Literature DB >> 10799578

Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1.

E Clark1, F Santiago, L Deng, S Chong, C de La Fuente, L Wang, P Fu, D Stein, T Denny, V Lanka, F Mozafari, T Okamoto, F Kashanchi.   

Abstract

Productive high-titer infection by human immunodeficiency virus type 1 (HIV-1) requires the activation of target cells. Infection of quiescent peripheral CD4 lymphocytes by HIV-1 results in incomplete, labile reverse transcripts and lack of viral progeny formation. An interplay between Tat and p53 has previously been reported, where Tat inhibited the transcription of the p53 gene, which may aid in the development of AIDS-related malignancies, and p53 expression inhibited HIV-1 long terminal repeat transcription. Here, by using a well-defined and -characterized stress signal, gamma irradiation, we find that upon gamma irradiation, HIV-1-infected cells lose their G(1)/S checkpoints, enter the S phase inappropriately, and eventually apoptose. The loss of the G(1)/S checkpoint is associated with a loss of p21/Waf1 protein and increased activity of a major G(1)/S kinase, namely, cyclin E/cdk2. The p21/Waf1 protein, a known cyclin-dependent kinase inhibitor, interacts with the cdk2/cyclin E complex and inhibits progression of cells into S phase. We find that loss of the G(1)/S checkpoint in HIV-1-infected cells may in part be due to Tat's ability to bind p53 (a known activator of the p21/Waf1 promoter) and sequester its transactivation activity, as seen in both in vivo and in vitro transcription assays. The loss of p21/Waf1 in HIV-1-infected cells was specific to p21/Waf1 and did not occur with other KIP family members, such as p27 (KIP1) and p57 (KIP2). Finally, the advantage of a loss of the G(1)/S checkpoint for HIV-1 per se may be that it pushes the host cell into the S phase, which may then allow subsequent virus-associated processes, such as RNA splicing, transport, translation, and packaging of virion-specific genes, to occur.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799578      PMCID: PMC110856          DOI: 10.1128/jvi.74.11.5040-5052.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

2.  Electroporation of viral transactivator proteins into lymphocyte suspension cells.

Authors:  F Kashanchi; J F Duvall; J N Brady
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

3.  Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins.

Authors:  W T Steegenga; A Shvarts; N Riteco; J L Bos; A G Jochemsen
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  Tat, a human immunodeficiency virus-1-derived protein, augments excitotoxic hippocampal injury in neonatal rats.

Authors:  P Wang; J D Barks; F S Silverstein
Journal:  Neuroscience       Date:  1999-01       Impact factor: 3.590

5.  The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.

Authors:  H Zimmermann; R Degenkolbe; H U Bernard; M J O'Connor
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes.

Authors:  Y D Korin; J A Zack
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.

Authors:  Y D Korin; J A Zack
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Binding of a host cell nuclear protein to the stem region of human immunodeficiency virus type 1 trans-activation-responsive RNA.

Authors:  M P Rounseville; A Kumar
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.

Authors:  L J Chang; E McNulty; M Martin
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

Authors:  E J Duh; W J Maury; T M Folks; A S Fauci; A B Rabson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more
  30 in total

Review 1.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

2.  Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.

Authors:  Sergey Iordanskiy; Fatah Kashanchi
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

3.  HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses.

Authors:  Edwige Col; Cécile Caron; Christine Chable-Bessia; Gaelle Legube; Sylvie Gazzeri; Yasuhiko Komatsu; Minoru Yoshida; Monsef Benkirane; Didier Trouche; Saadi Khochbin
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

4.  Primitive hematopoietic cells resist HIV-1 infection via p21.

Authors:  Jielin Zhang; David T Scadden; Clyde S Crumpacker
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

5.  Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.

Authors:  D Wang; C de la Fuente; L Deng; L Wang; I Zilberman; C Eadie; M Healey; D Stein; T Denny; L E Harrison; L Meijer; F Kashanchi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  9-Aminoacridine inhibition of HIV-1 Tat dependent transcription.

Authors:  Irene Guendel; Lawrence Carpio; Rebecca Easley; Rachel Van Duyne; William Coley; Emmanuel Agbottah; Cynthia Dowd; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  Virol J       Date:  2009-07-24       Impact factor: 4.099

7.  Inhibition of human immunodeficiency virus type-1 by cdk inhibitors.

Authors:  Irene Guendel; Emmanuel T Agbottah; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  AIDS Res Ther       Date:  2010-03-24       Impact factor: 2.250

Review 8.  Host hindrance to HIV-1 replication in monocytes and macrophages.

Authors:  Anna Bergamaschi; Gianfranco Pancino
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

Review 9.  Chromatin dynamics associated with HIV-1 Tat-activated transcription.

Authors:  Rebecca Easley; Rachel Van Duyne; Will Coley; Irene Guendel; Sherry Dadgar; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  Biochim Biophys Acta       Date:  2009-08-27

10.  Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1.

Authors:  Carter R Coberley; James J Kohler; Joseph N Brown; Joseph T Oshier; Henry V Baker; Michael P Popp; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.